Medicinal composition for treating hypertension

A technology of composition and medicine, which is applied in the field of medicine to achieve the effect of enhancing the therapeutic effect, improving the quality of life and reducing the dose

Active Publication Date: 2010-10-06
LUNAN PHARMA GROUP CORPORATION
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Chinese patent CN1883478 discloses a pharmaceutical composition for treating hypertensive cardiovascular disease, comprising levamlodipine and losartan, irbesartan, valsartan, eprosartan, candesartan or tasosartan Tan, and discloses that the pharmaceutical composition can...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating hypertension
  • Medicinal composition for treating hypertension
  • Medicinal composition for treating hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The preparation of embodiment 1 compound tablet

[0019] Levoamlodipine Besylate 4g

[0020] Losartan 44g

[0021] Lactose 18g

[0022] Microcrystalline Cellulose 150g

[0023] Cross-linked polyvinylpyrrolidone 10g

[0024] 10% starch slurry appropriate amount

[0025] Magnesium Stearate 2.5g

[0026] Preparation process: pass the levamlodipine besylate, losartan, lactose, microcrystalline cellulose and cross-linked polyvinylpyrrolidone in the prescription respectively through a 100-mesh sieve, mix well, add 10% starch slurry to granulate in an appropriate amount, 60 Dry below ℃, sieve through a 18-mesh sieve, add the prescribed amount of magnesium stearate, mix evenly, and compress into tablets.

Embodiment 2

[0027] The preparation of embodiment 2 compound tablet

[0028] Levoamlodipine Besylate 4g

[0029] Losartan Potassium 76g

[0030] Microcrystalline Cellulose 195g

[0031] Starch 25g

[0032] Sodium carboxymethyl starch 30g

[0033] Magnesium Stearate 3g

[0034] 5% PVP in absolute ethanol solution

[0035] Preparation process: first put levamlodipine besylate and starch into a mortar, grind and mix evenly, then add carboxymethyl starch sodium, microcrystalline cellulose and mix evenly, finally add losartan potassium and mix evenly, use 5% The anhydrous ethanol solution of PVP is used as a binder to granulate, dried at 40°C, granulated, mixed with magnesium stearate, and compressed into tablets.

Embodiment 3

[0036] The preparation of embodiment 3 compound capsules

[0037] Levoamlodipine Maleate 4g

[0038] Losartan Potassium 60g

[0039] Microcrystalline Cellulose 190g

[0040] β-cyclodextrin 20g

[0041] Micronized silica gel 2g

[0042] Preparation process: first put levamlodipine maleate and β-cyclodextrin into a mortar and grind and mix evenly, then add microcrystalline cellulose and micropowder silica gel and mix evenly, finally add losartan potassium and mix evenly, and fill the capsule Shell, that is.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal composition for treating hypertension, and belongs to the field of medicaments. The antihypertensive medicinal composition comprises a pharmaceutically effective dose of levoamlodipine or a pharmaceutically acceptable salt thereof and losartanpotassium, wherein the levoamlodipine is weighed in free alkali; the losartan is weighed in free acid; and the weight ratio of the levoamlodipine to the losartan is 1 to 11-19. The medicinal composition does not damage the target organ while reducing the blood pressure so as to enhance the therapeutic effect and reduce the risk for therapy of a patient.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a pharmaceutical composition for treating hypertension. Background technique [0002] Hypertension is the most common cardiovascular disease and has become a major public health problem worldwide. According to statistics from the national health department, by the end of 2006, the number of hypertensive patients in my country had reached 160 million, and more than 3 million new patients were added every year. [0003] Hypertension is a syndrome with very complicated etiology and pathogenesis. Once diagnosed, it requires life-long medication. At present, domestic and foreign medical circles generally tend to use two antihypertensive drugs with different mechanisms of action in combination. According to the sixth report of the National Committee on the Prevention, Detection, Evaluation, and Treatment of Hypertension, these antihypertensive small-dose fixed compound preparations can be used n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4422A61K31/4178A61P9/12
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap